Ambrx Biopharma Inc. Proceeds from Short-term Debt
Ambrx Biopharma Inc. reported Proceeds from Short-term Debt of $0 for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromShortTermDebt · last filed 2023-08-09
- Ambrx Biopharma Inc. proceeds from short-term debt for the quarter ending 2023-06-30 was $0.00.
- Ambrx Biopharma Inc. proceeds from short-term debt for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Ambrx Biopharma Inc. proceeds from short-term debt for the quarter ending 2022-06-30 was $0.00.
- Ambrx Biopharma Inc. proceeds from short-term debt for the quarter ending 2022-03-31 was $166.00M.
- Ambrx Biopharma Inc. proceeds from short-term debt for fiscal 2022 was $166.00M.
- Ambrx Biopharma Inc. proceeds from short-term debt for fiscal 2021 was $0.00.
| Period end | Proceeds from Short-term Debt 3 month | Proceeds from Short-term Debt 6 month | Proceeds from Short-term Debt 12 month |
|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | ||
| 2022-12-31 | $166.00M 10-K · filed 2023-03-30 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $166.00M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $166.00M 10-Q · filed 2023-05-11 | ||
| 2021-12-31 | $0.00 10-K · filed 2023-03-30 | ||
| 2021-06-30 | $0.00 6-K · filed 2022-08-29 |